Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

DATROWAY is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca’s ADC scientific platform. DATROWAY is comprised of a humanized ...

Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

AZ has already thrown down a marker for its tougher stance on Europe, with an earlier decision to abandon a $560 million ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

The US FDA has granted breakthrough device designation to Roche's companion diagnostic VENTANA TROP2 (EPR20043) RxDx Device.